
Clinical trials show that using voclosporin with mycophenolate mofetil is more effective at stopping lupus nephritis from getting worse than mycophenolate mofetil alone. This option is recommended for treating active class 3 to 5 lupus nephritis in adults. The cost-effectiveness estimates are within what NICE considers acceptable for NHS resources.
Recent Posts
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex Dynamics
Pharmaceutical innovation funding in the UK faces scrutiny amid industry claims that low NHS spending deters investments, but this narrative overlooks key drivers like scientific talent, tax incentives, and operational efficiencies rather than drug prices alone. A recent Lancet article critiques ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fair Resource Allocation
Health technology assessment plays a pivotal role in resource-constrained healthcare systems. How can organizations like NICE, ICER, and Canada's Drug Agency better incorporate novel value elements into economic evaluations? They can do so by adopting a principled framework that evolves beyond tr...